Testing blood and stool markers in active ulcerative colitis treatments
Treatments studied
Part of Digestive system clinical trials.
This study checks biomarkers (signals in blood and/or stool) in adults with moderate-to-severe ulcerative colitis. It compares patients starting targeted medicines and looks for marker patterns that may reflect how the disease is behaving.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older and have an established diagnosis of ulcerative colitis for at least 3 months
- Your ulcerative colitis is currently “moderate to severe” based on a symptom/score and also an endoscopy finding
- Your doctor plans to start a targeted medicine such as anti-TNF, anti-IL12/23, anti-integrin, or a JAK inhibitor
- If you take corticosteroids, your dose must be stable for at least 3 weeks and be 20 mg prednisone or less
- You must be able and willing to undergo endoscopy (a camera exam) for disease assessment as standard care
- Your baseline blood counts should not show significant anemia (hemoglobin below 10 g/dl)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at blood and/or tissue “molecular” (cell-level) reasons why treatments don’t fully work in adults with Crohn’s disease or ulcerative colitis. If you are starting a biologic or small-molecule medicine and still have moderate to severe symptoms, you may be able to contribute to research that helps improve future care.
This study looks for “biomarkers” (lab markers, like substances in blood or tissue) that may predict how Crohn’s disease or ulcerative colitis will go and how patients may respond. It may help doctors choose better monitoring or treatments in the future.
This study follows adults with Crohn’s disease or ulcerative colitis when their treatment is changed. It collects health information and samples to better understand how treatment changes affect people over time.
This study tests a new medication called BI 3032950 for people with ulcerative colitis who have already tried other advanced treatments (biologics or targeted therapies) that didn't work well enough or caused problems. The goal is to see if the new drug is safe and helps control inflammation in the colon.
This study looks at how your blood tests (inflammation levels) change after you start or adjust your treatment for ulcerative colitis or Crohn's disease. It also checks how your gut heals by looking at tissue samples from a follow-up colonoscopy.
This study looks at whether a special microscope used during a colonoscopy can help predict how well your ulcerative colitis will respond to a new type of medication called a small molecule. If you're starting this treatment, the results might tell you early if it's likely to work for you.
Hear when a new Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.